Status:
COMPLETED
An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Stroke, Ischemic
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of CV risk. We hypothesize that EC formulation based on the previous report may blunt aspirin res...
Eligibility Criteria
Inclusion
- Newly diagnosed ischemic stroke who are just about to start aspirin.
- No prior history of cardiovascular morbidity (including ischemic heart disease, chronic kidney disease, peripheral vascular disease) 3-18- 75 years.
- 4-Patients with ischemic stroke who underwent reperfusion intervention (catheter-directed thrombolysis and/or thrombectomy) regardless of the time of presentation (i.e within or outside the therapeutic window as the managing stroke deem fit.
Exclusion
- Concomitant antiplatelet therapy (irrespective of the duration of the treatment).
- Patients on any prostaglandins related medications (non-steroidal anti-inflammatory drugs, misoprostol, and other ant secretory drugs among others).
- Any salicylate-containing supplements.
- Patients on the NG tube will be excluded from the study
Key Trial Info
Start Date :
August 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 4 2020
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT04330872
Start Date
August 26 2019
End Date
March 4 2020
Last Update
April 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar, 3050